Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease
Next-generation CD40L and CD40-directed therapies are redefining costimulatory blockade in autoimmunity. Integrating preclinical discoveries with clinical translation offers new opportunities to optimize treatment and transform management of B cell-driven autoimmune disease.
Authors
- Sonali J. Bracken (ORCID: https://orcid.org/0000-0003-1814-4099)
- E. William St. Clair
Institutions
- Duke University (US)
- Center for Rheumatology (US)
Publication Details
- Journal
- Current Opinion in Rheumatology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/bor.0000000000001149
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.00